Aligos Therapeutics (ALGS) Q1 2026 earnings review
Amoytop Lifeline and Clinical De-Risking Keep the Engine Running
Aligos reported an Accelerating operating loss of $26.9M in 26Q1, driven by a 61% YoY surge in R&D expenses to fund the Phase 2 B-SUPREME trial. However, the company secured a vital lifeline: an exclusive licensing deal with Amoytop for Pevifoscorvir sodium in Greater China. The expected $25M upfront payment averts an immediate cash crunch, extending runway into Q4 2026. Clinically, Pevifoscorvir received FDA Fast Track designation and cleared its first interim futility analysis. The investment thesis hinges entirely on outlasting the cash burn to reach the 2027 Phase 2 topline data.
๐ Bull Case
Pevifoscorvir sodium cleared its first interim futility analysis with no viral breakthrough observed. The FDA's Fast Track designation further validates the potential for a best-in-class profile against chronic HBV.
The Amoytop deal secures a much-needed $25M upfront payment, unlocking up to $420M in milestones. This secures the balance sheet through Q4 2026 without immediate shareholder dilution.
๐ป Bear Case
The DSMB's recommendation to increase the Phase 2a trial size from 74 to 100 participants signals a need for higher statistical power, which will lengthen enrollment timelines and increase already heavy R&D burn.
The ALG-055009 (MASH) program remains unfunded. If management cannot secure a partner, the value of this asset will continue to decay while capital is hoarded for the HBV pipeline.
โ๏ธ Verdict: โช
Neutral. The Amoytop deal rescues the balance sheet and the clinical updates are positive, but rising trial costs and the DSMB's requested sample size increase introduce new execution risks.
Key Themes
Amoytop Partnership Secures Near-Term Runway
The exclusive license deal with Xiamen Amoytop Biotech for Pevifoscorvir sodium in Greater China is a game-changer for the balance sheet. Reversing the trajectory toward an imminent cash cliff, the $25M upfront payment extends the cash runway into Q4 2026. The deal also includes up to $420M in clinical, regulatory, and sales milestones plus tiered royalties, significantly reducing Aligos' geographic commercialization risk.
Pevifoscorvir Sodium Clears Early Hurdles
The Phase 2 B-SUPREME study (HBeAg- cohort) passed its first interim analysis. Futility criteria were not met, and no viral breakthrough was observed. Combined with the newly granted FDA Fast Track Designation, the clinical profile of this small molecule CAM-E remains highly promising as a backbone therapy for chronic HBV.
Next-Gen ASO Advances on Partner's Dime
ALG-170675, a dual-mechanism antisense oligonucleotide (ASO) targeting HBV, has entered IND-enabling studies. Crucially, current development costs in China are being funded by Amoytop. This allows Aligos to advance a highly innovative asset (targeting HBsAg-encoding mRNA while activating TLR-8) without exacerbating its own cash burn.
DSMB Sample Size Increase Hints at Statistical Power Needs
While the futility analysis was passed, the Drug Safety Monitoring Board (DSMB) recommended increasing the Phase 2a (HBeAg-) sample size from 74 to 100 participants. While management spins this as increasing the probability of success, it strongly suggests the observed effect size might be smaller or more variable than originally modeled, necessitating a larger 'N' to achieve statistical significance. This will increase trial costs and enrollment duration.
Accelerating R&D Cash Burn
R&D expenses are Accelerating dramatically, hitting $23.4M in 26Q1 compared to $14.5M a year ago. The jump is entirely driven by third-party expenses for the Pevifoscorvir Phase 2 trial. With the trial expanding by 26 participants per the DSMB recommendation, this burn rate is likely to remain structurally elevated, consuming the Amoytop upfront payment rapidly.
ALG-055009 (MASH) Remains in Limbo
Despite promising past Phase 2a data, ALG-055009 (THR-ฮฒ for obesity/MASH) remains unfunded. Management is still 'evaluating a variety of options' for out-licensing. Until a deal is signed, this asset is effectively stranded, generating zero value while competitors in the obesity/MASH space advance rapidly.
Other KPIs
Decelerating aggressively from $77.8M at the end of 25Q4. The company burned approximately $23M in a single quarter. The expected $25M upfront from Amoytop will replenish this, but the underlying cash consumption rate is severe.
Accelerating from $5.1M in 25Q1. While legal and related expenses decreased YoY, the overall corporate overhead remains a significant drag on resources for a pre-revenue biotech.
Guidance
Stable. Upgraded from prior guidance of 'into Q3 2026'. The extension is entirely dependent on the receipt of the $25M Amoytop upfront payment, which bridges the gap to the critical 2026 H2 interim data.
Management confirmed that the 50% enrollment threshold for the HBeAg+ cohort was reached in January 2026, setting the stage for the 24-week interim analysis readout in the second half of the year. This is the next major binary event for the stock.
Stable. The final readout for both cohorts remains on track for 2027, meaning the company must carefully manage its recently secured runway to reach this final validation point without needing a highly dilutive raise beforehand.
Key Questions
DSMB Rationale
The DSMB recommended increasing the Phase 2a sample size from 74 to 100. Was this driven by a higher-than-expected variance in the preliminary efficacy data, or simply an abundance of caution to ensure robust statistical significance?
ALG-055009 Partnership Timeline
With competitors advancing rapidly in the THR-ฮฒ and obesity space, what is the realistic deadline for securing an out-licensing partner for ALG-055009 before the asset's data becomes too stale to attract premium economics?
Amoytop Payment Timing
When exactly does the company expect to book the $25M upfront payment from Amoytop, and are there any regulatory hurdles in Greater China that could delay the transfer of these funds?